Ultragenyx Pharmaceutical Inc (RARE)

Jul 28, 2026

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Danaher (DHR) - The Globe and Mail

Jul 28, 2026

Jul 28, 2026

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline - Yahoo Finance UK

Jul 28, 2026

Jul 27, 2026

RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease - STAT

Jul 27, 2026

Jul 27, 2026

Ultragenyx Pharmaceutical, Inc. Revenue Breakdown – BIVA:RARE - TradingView

Jul 27, 2026

Jul 27, 2026

Ultragenyx Pharmaceutical Inc (RARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

Jul 26, 2026

RARE|Ultragenyx Pharmaceutical Inc|Price:26.900|Chg%:-0.120 - TradingKey

Jul 26, 2026

Jul 25, 2026

RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits

Jul 25, 2026

Jul 25, 2026

Ultragenyx Pharmaceutical Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh - TradingView

Jul 25, 2026

Jul 24, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Ultragenyx

Jul 24, 2026

Jul 24, 2026

Ultragenyx New Hires Get Stock Awards, 25% Vests Yearly - Stock Titan

Jul 24, 2026

Jul 24, 2026

Ultragenyx Pharmaceutical Inc (RARE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 24, 2026

Jul 24, 2026

Ultragenyx Pharmaceutical Inc (RARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026

Jul 22, 2026

Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail

Jul 22, 2026

Jul 21, 2026

Ultragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spree - Trefis

Jul 21, 2026

Jul 21, 2026

Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss - Trefis

Jul 21, 2026

Jul 21, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring an 84% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Jul 21, 2026

Jul 20, 2026

(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 20, 2026

Jul 20, 2026

RARE stock reflects Ultragenyx cash position and recent clinical progress - AD HOC NEWS

Jul 20, 2026

Jul 18, 2026

Ultragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focus - Sahm

Jul 18, 2026

Jul 17, 2026

Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024 -- Data Talk - Moomoo

Jul 17, 2026

Jul 17, 2026

RARE stock rises after Ultragenyx reports strong Crysvita revenue growth and narrows quarterly loss - Ad-hoc-news.de

Jul 17, 2026

Jul 15, 2026

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

Jul 15, 2026

Jul 15, 2026

Law firm probes Ultragenyx officers for alleged false statements on drug trial results - Pluang

Jul 15, 2026

Jul 15, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 15, 2026

Jul 15, 2026

BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $48 - Moomoo

Jul 15, 2026

Jul 13, 2026

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo

Jul 13, 2026

Jul 09, 2026

Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm

Jul 09, 2026

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa

Jul 08, 2026

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work - Investing.com

Jul 08, 2026

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times

Jul 08, 2026

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative

Jul 08, 2026

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire

Jul 08, 2026

Jul 08, 2026

Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan

Jul 08, 2026

Jul 07, 2026

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo

Jul 07, 2026

Jul 07, 2026

RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Jul 07, 2026

Jul 07, 2026

J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $72 - Moomoo

Jul 07, 2026

Jul 06, 2026

Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa

Jul 06, 2026

Jul 06, 2026

Form 4 Ultragenyx For: 6 July By Investing.com - Investing.com South Africa

Jul 06, 2026

Jul 06, 2026

Ultragenyx CFO Howard Horn sells $155,644 in company shares - Investing.com

Jul 06, 2026

Jul 06, 2026

Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake - Stock Titan

Jul 06, 2026

Jul 06, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 06, 2026

Jul 05, 2026

Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit - 富途牛牛

Jul 05, 2026

Jul 03, 2026

RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz

Jul 03, 2026

Jul 01, 2026

Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

Jul 01, 2026

RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan

Jul 01, 2026